A Randomised Phase II Study of MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease
The aim of the trial is to assess the benefit of adding high precision radiation therapy to chemotherapy and surgery for the treatment of pancreatic cancer.
Primary Sponsor
Australasian Gastro-Intestinal Trials Group (AGITG)
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG) and NHMRC CTC
Accrual Target
120
Expected Date of Accrual
31 December 2024
Trial Chairperson
Dr Andrew Oar, Gold Coast University Hospital
Trial Contact
MASTERPLAN.study@sydney.edu.au
Clinical Trial Registration
Related Post
10 June, 2026
Global cancer community prepares to unite for 2026 World Radiotherapy Awareness Day
LATEST NEWS: 10 June 2026 The global radiation therapy
4 June, 2026
Report showcases a year of impactful research, collaboration and consumer engagement
LATEST NEWS: 4 June 2025 TROG’s latest Annual Research